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ABSTRACT  
 
         Patients with Chronic Kidney Disease (CKD) can develop 
secondary hyperparathyroidism (sHPT), which is an adaptive response 
triggered by persistent alterations of the mechanisms that control the 
homeostasis of calcium (Ca), phosphorus (P) and vitamin D. In 
epidemiological studies, the prevalence of sHPT is based on mineral 
metabolism biochemical parameters and on serum intact parathyroid 
hormone (i-PTH) levels. Based on these parameters, the prevalence 
varies from 20-30% to 47-50%.             
          The primary objective of this study was to establish the 
epidemiology of a cohort of maintenance hemodialysis (MHD) and 
peritoneal dialysis (PD) patients. Secondary objectives of the study were: 
1) to integrate the biochemical and pharmacological data with the 
morphological data obtained by Ultrasonography with colorDoppler 
(US/CD) and 2) to establish the correlation between morphological and 
biochemical sHPT. We enrolled 395 patients, 269 males and 126 
females, 380 in MHD and 15 in PD. All patients underwent US/CD 
examination of the thyroid/parathyroid glands. The examination was 
performed by two experienced operators; single-blind (ICC 0.95-
intrapersonal, interpersonal-ICC 0.91). Epidemiological data were 
collected in a case report format. Mean dialytic age of population studied 
was 62.9 ± 71.3 months while mean predialytic CKD age was 91.4 ± 
82.7 months. Serum Ca was 8.9 ± 0.8 mg / dl, P 4.7 ± 1.5 mg / dl, Ca x P 
product 41.8 ± 15.0 mg2/dl2
           The prevalence of biochemical sHPT was 36.2% (143 patients out 
of 395) while the prevalence of morphological sHPT was 27.3% (108 
patients out of 395).  
, ALP 133.5 ± 93.1 IU/l and i-PTH 281.9 ± 
233.4 pg/ml.  
           According to the reference values recommended by the K-DOQI 
guidelines, 252 patients showed i-PTH serum levels ≤300 pg/ml (144.1 ± 
78.9  pg/ml) and 143 patients had i-PTH serum levels >300 pg/ml (526.6 
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± 215.9 pg/ml). Serum Ca levels did not differ significantly while P, Ca x 
P product and ALP were significantly different (P 4.6 ± 1.4 mg/dl vs 4.9 
± 1.7 mg/dl, p = 0.03, Ca x P 40.5 ± 13.8 mg2/dl2
 US/CD showed 173 parathyroid glands in 108 patients: 70 (64.9%) of 
them showed values of i-PTH >300 pg/ml and 38 (35.1%) values of i-
PTH ≤300 pg/ml. 73/287 (25.4%) patients showed values of i-PTH >300 
pg/ml, without hyperplastic parathyroid glands at US/CD.  
 vs 44.4 ± 16.6 p = 0.01, 
ALP 124.7 ± 87.2 IU/l vs 148.9 ± 101.1 IU/l, p=0.01).  
        The correlation between i-PTH and gland volume showed a linear 
trend (R2 = 0.1365, p = 0.001) regardless of current treatment (glandular 
volume = 0.8995 * (i-PTH) + 15.3). The biochemical evaluation 
associated with morphological examination with US/CD is the most 
complete diagnostic protocol for sHPT. So if i-PTH is constantly >400-
500 pg/ml, an US/CD evaluation of the neck should be performed in 
order to document the presence of hyperplastic glands. 
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INTRODUCTION 
 
 
Secondary hyperparathyroidism (sHPT) develops progressively during 
the course of chronic kidney disease (CKD). Phosphorus retention and 
reduced synthesis of 1–25 vitamin D3
Ultrasound with colorDoppler (US/CD) is the first choice imaging 
technique for the location and volume assessment of parathyroid glands, for 
the diagnosis of diffuse or nodular hyperplasia, as well as for clinical 
assessment of sHPT. 
 result in low serum calcium levels, 
which causes a feedback secretion of intact parathyroid hormone (iPTH). 
Long-term hyperstimulation of parathyroid glands enhances cell 
proliferation resulting first in diffuse polyclonal hyperplasia and finally in 
monoclonal nodular hyperplasia.  
 
ANATOMY AND EMBRYOGENESIS OF PARATHYROID GLANDS 
Anatomy 
Parathyroid glands are small endocrine glands with variable size and 
shape. They are located, two on each side (upper and lower parathyroid 
glands), on the posterior medial edge of the thyroid lobes. The average size 
of a normal gland is 5 x 3 x 1 mm, while the average weight is about 35 mg 
[1]. Glandular shape is often oval or spherical, but may even be oblong, 
lobed or multilobar. The parathyroid parenchyma of a young adult has a low 
amount of fat tissue and adipose stromal cells in normal glands are 
characterized by intracellular fat vacuoles at microscopic analysis. 
 Parathyroid glands have an arterial pedicle that penetrates into the 
gland at the hilum, where it can be divided into two or three branches. The 
parathyroid artery origins from the inferior thyroid artery in most cases (80 
to 90%). The inferior parathyroid gland can be feed by a branch from the 
arch of the aorta (middle thyroid artery), from the brachiocephalic trunk or 
from the ipsilateral internal mammary artery. The venous drainage is 
ensured by a subcapsular network which flows towards the hilum. Superior 
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parathyroid glands veins drain to the middle thyroid veins, while the inferior 
glands drain mostly in the inferior thyroid veins [2]. 
         The microscopic structure of parathyroid glands is characterized by 
strings of endocrine cells surrounded by connective tissue. Chief cells are 
the most represented cells. They are small (12-20 microns in diameter) and 
round, with a central nucleus and a cytoplasm that may look clear, pale or 
dark, depending on their functional status. Among chief cells, the most 
represented in normal conditions are the clear cells. The chief cells release 
parathyroid hormone (PTH). The chief cells biological activity is regulated 
by extracellular levels of calcium (Ca2+
           Normal parathyroid cells are characterized by a very low turnover 
[6]. They show a very slow rate of mitosis (slow apoptosis). Their average 
life span was estimated by Parfitt et al. using the nuclear antigen Ki-67. In 
human adults is approximately 20 years. [7]. Several studies have shown 
that regeneration does not exceed 5% of the cell population/year [8,9]. A 
recent analysis of samples of human parathyroid glands with the TUNEL 
technique showed an apoptosis rate of 1/10000 cells  [10,11]. 
). Finally, parathyroid parenchymal 
cells have oxyphil and transitional cells. These are slightly larger than chief 
cells, with a smaller central core and a cytoplasm rich in mitochondria and 
glycogen granules, but with very rare secretory vesicles, so they appear 
eosinophilic and easily detectable. The functional role of oxyphil cells has 
not yet been fully elucidated, although these cells have been recently 
identified as responsible for the synthesis of an i-PTH-related protein – 
(PTHrP) [3] that could act as an autocrine/paracrine regulator of 
proliferation [4,5]. In old subjects, fat tissue progressively replaces 
glandular cells, while in the newborn and infancy glands are composed 
almost entirely by chief cells. 
Several autoptic studies [2,12-16] show that the anatomical 
distribution of the parathyroid glands is relatively constant, especially for 
the superior glands located in most cases above the intersection between the 
recurrent laryngeal nerve and the inferior thyroid artery. In fact, superior 
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parathyroid glands are located in 77% of cases near the cricothyroid 
junction, above the intersection between the recurrent laryngeal nerve and 
the inferior thyroid artery, they are surrounded by fat tissue and show a long 
vascular pedicle; in 22% of cases they are rear of the upper pole of the 
ipsilateral thyroid lobe. In 1% of cases they are located in the 
retropharyngeal or retroesophageal space. The inferior parathyroid glands 
have a wider distribution than the superior ones. These glands are situated 
between the lower pole of the thyroid gland and the thymus and, rarely, if 
they have not migrated during the embryonic development, they are higher 
in the neck, close to the jaw. Only in rare cases parathyroid glands were 
found in the pericardial sac. The inferior parathyroid glands are located in 
42% of cases near the anterior or posterolateral surface of the inferior pole 
of the thyroid gland. Here, parathyroid glands are frequently masked by 
vessels or by the thyroid tissue. In 39% of cases, they are contained in the 
fat tissue between the lower pole of thyroid gland and the thymic horn or 
they are close to the thymus in the superior mediastinum. In 15% of cases, 
then, they are distributed in the iuxtathyroid space, lateral to the inferior 
thyroid pole. Other more rare ectopic locations are the mediastinum, the 
intrathyroid or prethyroid, retropharyngeal and retroesophageal space. In 
only 8% of cases the inferior glands can be above the junction between the 
laryngeal nerve and the inferior thyroid artery. 
 
Embryogenesis 
       The knowledge of the embryonic development of the parathyroid 
glands is essential for the diagnosis and surgical management of 
hyperparathyroidism. It explains the different glandular locations, especially 
those related to an abnormal embryological migration which occurs in 2-5% 
of cases and leads to surgical failure. Parathyroid glands originate from the 
interaction of neural crest mesenchyme and third and fourth branchial pouch 
endoderm. The superior parathyroids arise from the fourth pharyngeal 
pouch, and the inferior parathyroids arise from the third pharyngeal pouch 
together with the thymus. Inferior parathyroid glands in the adult can be 
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located from the corner of the jaw to the area near the thymic space in the 
anterior superior mediastinum. Superior parathyroids maintain a more 
cranial and constant location, close to the posterior edge of the thyroid lobe, 
near the inferior thyroid artery [17].  
 
PHYSIOPATHOLOGY OF sHPT 
 
In literature, the prevalence of sHPT in haemodialysis patients is 
highly variable, from 20-30% [18] to 47-50% [19,20]. 
In normal conditions, parathyroid cells are quiescent with a low grade 
of mitotic divisions [8,21]. Therefore, many biochemical stimuli determine 
a rise of i-PTH secretion by an immediate release of preformed vesicles (in 
few minutes), then they determine the transcription of i-PTH-mRNA (few 
hours) and finally they induce a modification of the replication rhythm. 
These stimuli are: 
1. Hypocalcemia and a high ionized calcium set-point (ie the average 
concentration of Ca2+
2. Reduced synthesis of 1-25 (OH)
 that inhibits by 50% the secretion of PTH). In patients 
with sHPT the calcium-PTH sigmoidal curve is shifted to the right, so 
higher serum calcium levels are required to suppress the secretion of i-PTH  
[22,23].  Changes in the calcium-PTH balance and calcium set-point appear 
late in the course of CKD and they characterize patients with severe sHPT 
[24]. Furthermore, hypocalcemia is responsible for a post-transcriptional 
regulation of i-PTH  [25]. 
2 vitamin D3 in the kidney [26]. 
Hyperphosphatemia, the loss of renal mass and an increase in FGF-23 
reduce the activity of α1-hydroxylase. Consequently, decreased serum levels 
of 1-25 (OH)2 vitamin D3 determine a reduced intestinal absorption of 
calcium, which contributes to hypocalcemia and to an insufficient activation 
of the parathyroid glands receptors for the 1-25 (OH)2 vitamin D3 (Vitamin 
D Receptors - VDR), resulting in an increased transcription of PTH mRNA 
and then increase in its synthesis [27].  
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3. Hyperphosphatemia. According to the “trade-off” theory, the retention 
of phosphate induces a reduction in serum Ca2+ levels. 
4. The reduced density of calcium membrane receptors (calcium-sensing 
receptors - CSR) [26] of parathyroid cells. 
Experimental animal 
studies have also documented a direct action of phosphorus on parathyroid 
cells [28]: hyperphosphatemia is responsible for an increase in the PTH 
gene transcription, acting at a post transcriptional level [25]. 
Hyperphosphatemia also represents the main inhibitory stimulus for vitamin 
D activity. 
5. The reduced concentration of receptors for the 1-25 (OH)2 vitamin 
D3
6. The increase of Fibroblast Growth Factor 23 (FGF-23) serum levels. 
FGF-23 is a 251 amino acids protein that in humans is encoded by the 
FGF23 gene. FGF23 is a member of the fibroblast growth factor (FGF) 
family which is responsible for phosphate metabolism. 
 (calcitriol) [29].  
      Recent studies have shown a positive correlation between the 
progressive decline of renal function and the gradual increase in serum 
intact FGF-23 [30-32]. In hemodialysis patients FGF-23 is markedly 
increased, demonstrating a positive correlation with PTH and phosphorus. 
FGF-23 is a reliable screening test to identify patients who, within two 
years, will develop refractory secondary hyperparathyroidism [33]. Kazama 
JJ et al. have attribute to FGF-23 the additional role of marker for the 
resistance to treatment with intravenous calcitriol in patients with sHPT 
[34]. FGF-23 has the following functions: a) it inhibits the activity of 
tubular Na-P cotransporters, decreasing the reabsorption of phosphate and 
thus increasing its excretion; b) it reduces the expression of renal 1α-
hydroxylase inducing, therefore, a negative feedback on 1-25 (OH)2 vitamin 
D3; c) it induces the synthesis of 24-hydroxylase that degrades 1-25 (OH)2 
vitamin D3 [35]; d) FGF-23 directly inhibits, in vivo and in vitro, the 
expression of PTH gene and the secretion of PTH  [36,37]. The mechanism 
of action of FGF-23 is not yet completely clear, but it seems that it acts 
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through a specific receptor (FGF-R) expressed in the kidney, parathyroid 
and pituitary gland and choroid plexus. However, the affinity of FGF-23 to 
its receptor is quite low so a cofactor (Klotho protein) is needed. The effects 
of this protein are not fully elucidated, but it seems to be involved in the 
processes of aging.  
In uremic patients, parathyroid cells are under continuous stimulation 
by hyperphosphatemia, hypocalcaemia, reduced synthesis of vitamin D3
The relationship between gland volume and indices of hormonal 
secretion is also well known [41]. In fact, the basal calcium-independent 
secretion of PTH positively correlates with the glandular size [42]. Serum i-
PTH levels become able to overcome the skeletal resistance, thus 
determining a bone resorption. Despite the increase in serum calcium and 
phosphorus, parathyroid resistance to negative feedback of calcium allows i-
PTH secretion to progressively increase. According to international 
guidelines, parathyroidectomy becomes mandatory when one or more 
parathyroid glands are enlarged in volume (>500 mm
 and 
reduced expression of VDR and CSR. Long-term hyperstimulation of 
parathyroid glands produces glandular hyperplasia which is polyclonal at 
first and then monoclonal and nodular, progressing into a growth disorder 
(tertiary hyperparathyroidism) [38,18]. The evolution from diffuse 
polyclonal to nodular monoclonal hyperplasia/hypertrophy is accompanied 
by a further reduction in the density of CSR and especially of VDR; this 
different gene expression is responsible of the resistance to medical therapy 
with calcitriol [39]. Nevertheless, the pathogenesis and the progression of 
sHPT have a multifactorial etiology. Other etiologic and still unknown 
factors (probably genetic mutations) may play a role. In fact, several 
deletions of chromosome 11 have been identified in parathyroid glands of 
patients with tertiary hyperparathyroidism [40].  
3
 
), i-PTH >700 pg/ml 
and the parameters of the mineral metabolism are no longer controlled by 
conventional therapy [43-45]. 
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CLINICAL CONSEQUENCES OF sHPT 
 
The lack of control on mineral metabolism and on serum i-PTH has 
important skeletal and extra-skeletal consequences in uremic patients. In the 
first group we include fibrocystic osteitis, mixed uremic osteodystrophy and 
adynamic bone disease, and the second group includes cardiovascular and 
soft tissue calcifications, endocrine abnormalities, impaired immune system, 
erythropoiesis abnormalities and neuromuscular disease. sHPT plays a very 
important role in the pathogenesis of cardiovascular disease which is the 
leading cause of morbidity and mortality in the uremic population. 
 
 Uremic osteodystrophy 
 The term “uremic osteodystrophy” includes all skeletal diseases in 
patients with CKD, characterized by an accurate histo-morphometric study 
of bone biopsy. Almost all uremic patients show heterogeneous histological 
bone abnormalities, divided into two groups: bone diseases with high or low 
turnover. Diseases with high bone turnover are fibrocystic osteitis and 
mixed uremic osteodystrophy. Low turnover bone diseases are osteomalacia 
and adynamic bone disease. The prevalence of the different forms of 
osteodystrophy has changed in the last decades: mixed uremic 
osteodystrophy and adynamic bone disease (ABD) are predominant 
nowadays, while osteomalacia has almost disappeared and has been 
replaced by ABD. Normally, the risk of a high bone turnover disease 
increases with the increase of i-PTH serum levels [46,47]. However, the 
ability to predict that there is a high bone turnover disease is poor until i-
PTH serum levels do not reach 450-500 pg/ml. Instead, i-PTH serum levels 
<100 pg/ml are suggestive of a low bone turnover disease. 
 
High turn-over bone disease. Fibrocystic osteitis is characterized by a high 
rate of bone formation and resorption, an increased osteoclast and osteoblast 
activity and a progressive increase in peritrabecular marrow fibrosis. The 
bone erosion can occur in any district, but phalanges and skull are the most 
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common locations. Sever fibrocystic osteitis may be associated with brown 
tumors, which are pseudotumoral lytic lesions with haemorrhage and 
necrotic phenomena and it is associated with a high incidence of 
pathological bone fractures, especially vertebral.  
       Mixed uremic osteodystrophy is characterized by some aspects of a 
high turnover osteodystrophy associated with mineralization defects and an 
increase in bone formation. The hystological abnormalities show different 
degrees in every patient, but in all of them there is a coexistence of fibrotic 
areas with increased bone remodeling and deposition of low-mineralized 
bone matrix [48]. 
Low turn-over bone diseases. ABD is nowadays the most prevalent form 
of bone disease associated with CKD in haemodialysis patients. The 
histologic features of ABD are the absence of osteoblastic and osteoclastic 
activity and a poor production of bone matrix [48]. An excessive 
suppression of i-PTH due to the use of phosphate binders and calcium-based 
dialysis baths containing high concentrations of calcium inhibit a bone 
structure which already has a very low turnover, as it occurs in 
haemodialysis patients. Therefore, skeletal structures are unable to absorb 
serum calcium and bones appear more fragile. The etiology remains 
unknown but risk factors are age, diabetes mellitus and excessive use of 
phosphate binders containing calcium and vitamin D. In addition, 
osteoblasts show an abnormal response to i-PTH due to downregulation of 
the PTH receptor [49], which further contributes to the poor cellularity that 
characterizes ABD. 
        Symptoms associated with renal osteodystrophy usually appear with 
severe CKD. Bone and joint pain progressively worsen and they finally 
determine walking inability. Itching is due to the deposition of calcium in 
renal failure, especially in patients with severe hyperparathyroidism  
[50,51]. 
 Extra-skeletal consequences 
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          Foley [52] has demonstrated that the risk of cardiovascular mortality 
in dialysis patients is approximately 10-20 times higher than in the general 
population, particularly in younger subjects. 
Vascular calcification. Vascular calcification is a physiopathological 
mechanism that can explain the high mortality. Although all forms of 
uremic osteodystrophy are associated with vascular mineralization, the 
association between low-turnover osteodystrophy and arterial calcification 
is important: in fact, skeletal osteoblast function is deficient in ABD, but 
there is an osteoblastic differentiation of intimal-medial muscle cells that 
surround the atherosclerotic plaque. Vascular calcification is associated with 
four parameters in dialysis patients: hyperphosphatemia, hypercalcemia, 
elevated Ca x P product and oral intake of calcium. 
1. Hyperphosphatemia, a major independent risk factor for cardiovascular 
disease, directly stimulates the calcification process and it induces the 
proliferation of smooth muscle cells  [53]. Block et al. [54] demonstrate that 
over 60% of dialysis patients have a phosphatemia >5.5 mg/dl and patients 
with values >6.5 mg/dl have a higher risk of mortality by 27% compared 
with subjects with phosphorus ranging from 2.5 to 6.5 mg/dl. 
2. There is a linear relationship between serum calcium levels and 
cardiovascular mortality [55], probably linked to the calcium availability for 
the mineralization process [56]. The clinical consequences of these 
observations are clear if we consider that, except for calcimimetics, all 
therapeutic strategies that reduce PTH serum levels, such as vitamin D and 
calcium based phosphate binders, are often associated with an increase in 
serum calcium and Ca x P product [57]. 
In the general population, vascular disease may be due to different 
pathological processes associated with calcification: atherosclerotic disease 
and Mönckeberg medial calcific sclerosis. In atherosclerotic disease, 
characterized by wall fibro-fatty plaques, calcification is a late event [58]. 
However, atherosclerosis can also be a circumferential lesion (with no 
obstruction of the lumen) with calcification occurs earlier in the course of 
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the disease [59]. Mönckeberg calcific sclerosis of small and medium elastic 
arteries shows circumferential calcifications that appear like thin rings at X-
ray scan [60]. Recent studies have clearly demonstrated that this form of 
medial calcification in distal vessels is associated with increased 
cardiovascular mortality in diabetic patients without chronic renal failure, 
[61] and in patients with chronic renal failure [62]. 
Recently it has been suggested that both vascular diseases have a 
unique physiopathological process [63]. In fact there is a dynamic process, 
not just a degenerative mechanism due to a passive deposition of calcium. 
The first step is the dedifferentiation of smooth muscle cells into osteoblast-
like cells. These osteoblast-like cells produce type I collagen and non 
collagenous matrix proteins, which can regulate the mineralization process. 
The increase of CaxP product, sHPT or an excessive calcium intake may 
accelerate this process. Following to this theory, mineralization begins when 
promoting factors exceed inhibiting factors [64]. 
       Calcified uremic arteriolopathy (CUA) of small vessels of skin, 
subcutaneous fat, and skeletal muscle determines ulcerative lesions that 
progress toward ischemic necrosis. In patients with CUA the mortality rate 
ranges from 45 to 65% and even higher in presence of ischemic lesions. 
Further studies have shown structural and functional myocardial 
abnormalities, including fibrosis and calcification, associated with 
hyperphosphatemia and excessive calcium load in hemodialysis patients 
[65]. 
 
Role of PTH and cardiovascular risk in sHPT. The wide range of cellular 
and tissue effects associated with increased serum PTH led to consider it as 
a uremic toxin [66]. High serum i-PTH levels (>65 pg/ml) in CKD patients 
are associated with a high risk of cardiovascular mortality, regardless 
phosphatemia and vitamin D therapy [67,68]. i-PTH has specific receptors 
on myocytes, and this direct effect causes an increase in intracellular 
calcium concentrations and rises the frequency and strength of muscle 
contraction [69]. Finally, it determines an increased interstitial collagen 
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tissue and a myocyte hypertrophy [70]. Left ventricular mass (LVM) and 
LVM indexed to height (LVMI) are higher in patients with hypertension and 
high serum levels of i-PTH [71]. PTH is also able to play an active role in 
the deposition of calcium in the myocardium, and in valvular and vascular 
structures [72-74].  
  
 Metastatic calcifications. The systemic consequences of sHPT must be 
summed to all clinical consequences of the uremic state. Calcium-
phosphorus metabolism and bone turnover abnormalities are associated with 
cutaneous, renal, pulmonary and cardiovascular metastatic calcifications, 
which are expression of the reduced bone formation, i.e. an excessive 
skeletal remodeling with increased serum levels of Ca, P and Ca x P product 
[75]. Heterotopic calcifications may occur in many soft tissues: cornea (band 
keratopathy), conjunctiva (red-eye syndrome), lung (restrictive syndrome), 
myocardium (arrhythmias, valvular calcifications), articular and periarticular 
structures, and tendons (joint pain and functional impairment, partial or 
complete rupture of the quadriceps muscle tendons or of the Achilles 
tendon). 
Other clinical consequences of sHPT. sHPT is also involved in glucose 
intolerance because i-PTH decreases the production of insulin, by increasing 
the concentration of intracellular calcium in pancreatic islet cells [76]. 
         Some studies have also shown an immunosuppressive action of i-PTH 
[77] with decreased neutrophil phagocytic capacity and susceptibility to 
infections. The increased concentration of intracellular calcium reduces the 
synthesis of ATP on the mitochondrial respiratory chain [78]. Moreover, 
there are also functional abnormalities of macrophages, immunoglobulins, 
platelets and T lymphocytes [76]. 
         Patients with severe sHPT show a refractory anemia which requires 
higher doses of recombinant erythropoietin (EPO). This refractory anemia, 
not responsive to EPO, significantly improves after parathyroidectomy [78-
80]. The main cause of this reduced treatment response is osteodystrophy 
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and bone marrow fibrosis with consequent reduction of erythroid cells [80]. 
However, studies have also suggested a possible direct toxic effect of i-PTH 
on erythropoietic bone marrow [81]. 
        High i-PTH and intracerebral calcium serum levels are responsible for 
some manifestations of uremic encephalopathy, but mechanism involved are 
still unknown [82]. Some experimental data suggest that i-PTH interferes 
with normal neurotransmission, by promoting the entry of calcium in the 
central nervous system [83]. 
TREATMENT OF SECONDARY HYPERPARATHYROIDISM 
 
Treatment of sHPT has two objectives: a. short-term objectives 
(maintenance of optimal values for i-PTH, calcium, phosphorus, prevention 
of parathyroid hyperplasia and of skeletal abnormalities); b. long-term 
objectives (reduction of cardiovascular morbidity and mortality).  
In most cases, the reference ranges given by the K/DOQI guidelines 
for iPTH, P, Ca serum levels and CaxP product in haemodialysis patients 
are not achieved, as reported by the European multicenter observational 
analysis (COSMOS) based on 4500 patients [84] and the recent Italian 
Survey of the FARO Study Group based on 2637 patients [85]: only 30% of 
patients reaches the target for i-PTH and 50% for calcemia and 
phosphatemia. 
 
Biochemical parameters Range  
i-PTH 150-300 pg/ml 
Ca 8,4-9,5 mg/dl 
P 3,5-5,5 mg/dl 
Ca X P <55 mg2/dl2 
 
KDOQI guidelines reference ranges for i-PTH, P, Ca e CaXP product in 
haemodialysis patients. I-PTH: 1 pmol/l =1 pg/ml x 0,105; Ca: 1 
mmol/l = 1 mg/dl x 0,25;P: 1 mmol/l = 1 mg/dl x 0,323. 
 
Current treatment strategies rely on three drug families, based on the 
pathophysiological mechanisms of sHPT: 
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1. Phosphate binders. They are used in 90% of hemodialysis patients 
[86], because dialytic clearance and intake reduction of phosphorous 
(without causing malnutrition) are not sufficient alone to control 
hyperphosphatemia. 
Aluminium salts (AlOH3
The K/DOQI guidelines [89] suggest that the maximum amount of 
calcium (used as a phosphate binder) must not exceed 1500 mg per day, 
while the K-DIGO new guidelines [90] do not set a specific limit, but they 
recommend to reduce the amount of calcium-based binders in case of 
hypercalcemia, vascular calcification, adynamic bone disease or low serum 
i-PTH levels. Sevelamer has been the first calcium and aluminium free 
phosphate binder that shows the same efficacy of calcium carbonate in 
controlling hyperphosphatemia, but at the same time it reduces the  
) are probably the most effective phosphate 
binders in reducing the intestinal absorption of phosphate. However, other 
effects of aluminium salts as potential neurotoxicity of aluminum, anemia 
and its accumulation at the site of osteoid mineralization, which results in 
severe osteomalacia and ABD, have limited their use in clinical practice. 
Calcium salts (carbonate and acetate) are frequently used, and they are well 
tolerated but there is a risk of a positive calcium balance, hypercalcemia in 
near 50% of patients (especially when it is used at high doses and in 
association with vitamin D analogues), and vascular calcifications [87]. 
They can also determine an excessive suppression of i-PTH, increasing the 
risk of  ABD [88]. 
Lanthanum carbonate is a salt formed by lanthanum cations and 
carbonate anions and it is used in Europe since 2006. It has demonstrated a 
high gastrointestinal phosphate binding capacity and a higher efficacy to 
that of sevelamer and of calcium carbonate. Its efficacy means fewer pills to 
take so it increases the patient compliance towards binding therapy. 
2. Calcium supplements. The administration of calcium supplements 
(calcium carbonate or calcium acetate) may be effective in controlling the i-
PTH serum levels in some dialysis patients and in some cases of CKD stage 
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5. The use of calcium is limited due to the increased risk of vascular 
calcification. 
3. Activators of the VDR (VDRA). Calcitriol therapy in sHPT inhibits the 
synthesis of parathyroid hormone and the parathyroid hyperplasia [91], and 
it is used in clinical practice since the '80s, but its use is accompanied by the 
risk of hypercalcemia and hyperphosphatemia determine due to the increase 
in intestinal calcium and phosphorus absorption, which determines the 
development or progression of vascular calcifications, especially if there is 
an excessive suppression of bone turnover [92]. In the last decade, in order 
to minimize such negative effects, many new molecules have been 
introduced in drug therapy (paricalcitol, dorxecalciferol, alphacalcidol). 
They determine a selective activation of VDR and they maintain the 
inhibitory activity on the parathyroid gland but have minor effects on the 
intestinal transport of calcium and phosphorus, due to a different affinity for 
the vitamin D binding protein and the nuclear receptor. Paricalcitol is used 
in Europe for intravenous injection in hemodialysis patients, although it was 
also approved for oral administration even in the early stages of CKD. Some 
experimental studies suggest that paricalcitol is more effective than 
calcitriol in sHPT: a) minor influence on serum calcium and phosphorus 
[93];  b) different effects on cardiovascular tissues in terms of inhibition of 
proliferation of vascular smooth cells [94] and reduced induction of the 
processes of vascular calcification [95], suppression of the renin-angiotensin 
system, inhibition of myocytes proliferation; c) reduced risk of ABD [96]. It 
is however important to remember that there is a reduction of VDR in 
patients with parathyroid nodular hyperplasia, so vitamin D/analogues in 
patients with severe sHPT are less effective [97]. 
The definition of severe sHPT is based on the inadequate control of 
serum levels of Ca, P, Ca XP and i-PTH with conventional therapy 
associated with a significant increase in cardiovascular risk [98]. Following  
international guidelines, in fact, parathyroidectomy is mandatory when 
conventional therapy does not control mineral metabolism parameters, as 
well as the finding of a gland volume >500 mm3 and values of i-PTH >700 
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pg/ml [99,100]. Many observational studies highlight the failure to achieve 
and/or to maintain with conventional treatment the targets indicated by the 
K-DOQI guidelines [101,102] and they suggest the necessity of adding 
calcimimetics to the conventional therapy. 
  
 Calcimetics: a new era 
Calcimimetics are a family of ligands that mimic or enhance on CaSR 
the effects of extracellular Ca2+
Pharmacodynamics. The biological activity of calcimietics is due to 
the interaction with the transmembrane part of the receptor (6
. Class I includes calcimimetics that directly 
stimulate the receptor interacting with its extracellular domain. 
Calcimimetics of class II (NPS R-467, S-467, R-568, S-568, AMG 073) are 
allosteric activators of CaSR, which in parathyroid cells is the main 
regulator of the rapid secretion of preformed PTH [103].  
th and 7th
PTH decreases soon after administration of cinacalcet, reaching the nadir 
about 2-6 hours later, at the Cmax of cinacalcet. Later, while reducing the 
levels of cinacalcet, PTH levels increase up to 12 hours after administration, 
then the suppression of PTH remains approximately constant until the end 
of the dosing interval (24 hours). Once the steady state has been reached, 
serum calcium levels remain constant over the dosing interval. 
 
transmembrane domain) that induces some conformational changes of the 
extracellular portion (N-terminal) of the receptor itself. The binding of the 
calcimimetic with CaSR increases the sensitivity of the receptor to 
extracellular calcium and therefore it determines a shift to the left of the 
sigmoidal curve, which describes the relationship ionized calcium-PTH. 
This action determines a reduction of the calcium set point and finally an 
inhibition of PTH secretion [104]. Cinacalcet (AMG 073) is the only 
second-generation calcimimetic used in clinical practice since 2004 in the 
USA and since 2005 in Europe and it is able to reduce i-PTH and calcium 
serum levels, without increasing the intestinal absorption of calcium and 
phosphorus. This characteristic distinguishes it from calcitriol and similar 
vitamin D analogues [105].  
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Pharmacokinetics. Based on comparisons between different studies, 
it was estimated that cinacalcet has an absolute bioavailability in fasting 
subjects that reaches approximately 20-25%. The administration of 
cinacalcet with food determines an increase in the bioavailability of 
approximately 50-80%. Increases in plasma concentration of cinacalcet are 
similar, regardless of the fat content of foods. After absorption, cinacalcet 
concentrations decline in a biphasic way, with an initial half life of about 6 
hours and a terminal half life of 30-40 hours. The steady-state drug levels 
are achieved within 7 days, with a very low accumulation. The AUC and 
Cmax of cinacalcet increase in a linear way in the dose range (from 30 to 
180 mg once daily). The absorption is saturated at doses above 200 mg, 
probably due to a poor solubility. The pharmacokinetics of cinacalcet does 
not change over time. The volume of distribution is about 1000 liters, 
indicating a large distribution. Cinacalcet is bound to plasma proteins for 
about 97%. Cinacalcet is metabolized by multiple enzymes, primarily 
CYP3A4 and CYP1A2. The major circulating metabolites are inactive. 
Cinacalcet is rapidly and extensively metabolized by oxidation followed by 
conjugation. The renal excretion of metabolites is the predominant route of 
elimination of cinacalcet. There are no clinically relevant differences in the 
pharmacokinetics of cinacalcet due to age. The pharmacokinetic profile of 
cinacalcet in patients with CKD stage 1,2,3,4 and those on hemodialysis or 
peritoneal dialysis is similar to that found in healthy volunteers. Mild 
hepatic dysfunction does not affect the pharmacokinetics of cinacalcet. 
Compared to subjects with normal liver function, the mean AUC of 
cinacalcet is approximately 2 times higher in subjects with mild dysfunction 
and approximately 4 times higher in patients with severe hepatic 
dysfunction. In patients with mild and severe hepatic dysfunction the 
cinacalcet half life is longer respectively 33% and 70%. The protein binding 
of cinacalcet is not affected by liver disease. Since the dose is titrated for 
each subject based on the parameters of safety and efficacy in patients with 
liver dysfunction any further adjustment of the dose is not needed. The 
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clearance of cinacalcet is higher in smokers than in non smokers, probably 
due to induction of CYP1A2-mediated metabolism.  
       The cumulative analysis of 3 studies in phase 3 (1136 dialysis patients 
treated for 26 weeks) has demonstrated the effectiveness of the use of 
cinacalcet vs placebo in the control of sHPT, with a reduction in PTH of 
40% vs 6%, which was associated with a reduction (6.8%) of serum 
calcium, of serum phosphorus (8.4%) and of CaXP product (15%) [106]. 
The OPTIMA randomized prospective study [107] showed that cinacalcet 
added to conventional therapy determines a significant increase in the 
percentage of patients that reach the target for i-PTH, calcium and 
phosphorus (according to the K-DOQI guidelines): 71% of patients in the 
group treated with conventional therapy and cinacalcet reaches a value of i-
PTH <300 pg/mL compared to 22% of the control group. The stimulation of 
CaSR also inhibits the synthesis of i-PTH with a post-transcriptional 
mechanism [108], and inhibits the proliferation of glandular cells [109]. 
Calcimimetic also determines an up-regulation of CaSR and VDR on 
parathyroid cells [110,111], which potentially improves the therapeutic 
response to calcitriol. The EVOLVE clinical trial will assess the effects of 
the improvement obtained with cinacalcet on biochemical parameters of 
mineral metabolism and on the clinical outcomes, such as mortality and 
cardiovascular events in dialysis patients. The aim of another prospective 
randomized study in progress on 330 subjects (ADVANCE) is to test the 
hypothesis that treatment with cinacalcet attenuates the progression of 
vascular calcification in dialysis patients, as suggested by experimental 
studies in animals [112]. Moreover, cinacalcet seems to improve the 
histological bone turnover and to reduce the excessive marrow fibrosis in 
most patients with sHPT [113]. The hypothesis derived from preclinical 
studies [114,115] about the possibility that cinacalcet could induce 
regression of parathyroid hyperplasia has been also evaluated in humans 
[116]. Cinacalcet has a more rapid effect on biochemical profile of severe 
sHPT than on the morphology of the gland. In fact, the control of 
biochemical parameters is reached quickly, while the changes in volume, 
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ultrasonographic and vascular pattern appear only after 12-18 months. The 
most significant volume changes, however, are found in parathyroids with a 
starting volume <500 mm3, while in larger glands (>500 mm3
Cinacalcet modulates the biology of parathyroid cells in synergy with 
vitamin D and phosphate binders, and leads to the appearance of 
degenerative phenomena and glandular hypovascularisation. The 
pathophysiological mechanisms responsible for cystic degeneration and 
reduction of blood supply may find an explanation in an increased apoptosis 
[117,118], although it is not possible to exclude an indirect effect of 
cinacalcet on the vascular tree due to an interaction with endothelial CaSR  
[119]. Persistent receptor stimulation is also needed to achieve the control of 
mineral metabolism. In fact, the secretory rebound, appeared after the 
temporary suspension of cinacalcet, could be explained by the persistence of 
a functioning cell mass which is strongly stimulated by the suspension of 
the drug. The therapeutic response should be therefore monitored not only 
with biochemical but also with morphological parameters. It is also 
) prevail 
involutive phenomena with the appearance of areas of cystic degeneration. 
In most cases, the ultrasonographic pattern changes from hypoechoic 
(suggestive of glandular hyperplasia with increased number of secreting 
cells) towards hyperechoic (cells become quiescent with an increase number 
of oxyphil cells and of adipocytes). It's interesting to observe that the glands 
showed a reduction in blood flow after treatment with cinacalcet regardless 
of the starting volume, and they reproduced in a reverse way the progression 
towards parathyroid hyperplasia (from hypoechoic to hyperechoic 
ultrasonographic pattern, and from hypervascularized to non vascularized 
color Doppler pattern). In any case, the most important morphological 
changes coincided with the most marked reduction of i-PTH and calcium 
serum levels, suggesting a major responsiveness in these cases. In some 
patients with these characteristics a lower dose than the minimum dose 
currently available (30 mg/day) was needed. It would be important in the 
future to start cinacalcet earlier and with lower doses, in combination with 
conventional therapy. 
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important to perform a long-term therapy to achieve a "pharmacological 
parathyroidectomy" that could reduce the number of patients who undergo 
surgical parathyroidectomy.  
 
DIAGNOSIS OF SECONDARY HYPERPARATHYROIDISM  
 
              Diagnosis of biochemical sHPT is based on the evaluation of 
changes in calcium-phosphorus balance: hypocalcemia, hyperphosphatemia, 
decreased 1-25 (OH)2 vitamin D3 and increased i-PTH. In fact, there is a 
linear relationship between non-suppressible i-PTH secretion and glandular 
volume [41]. Imaging techniques allow understanding the clinical aspects of 
sHPT, thus reaching two purposes: a. anatomical location, number and 
morphology of hyperplastic parathyroid glands, and b. clinical condition of 
the target organ damaged by the imbalance of mineral metabolism (arteries, 
heart, bones, muscles, skin). However, the morphological diagnosis of sHPT 
may present several difficulties: 
 
1. elevated i-PTH serum levels are not 
always synchronous with volumetric growth of parathyroid glands; 2. 
imaging techniques for the study of parathyroid glands (US/CD 
ultrasonography, scintigraphy, CT, MRI)may present difficulties of 
implementation and interpretation of the results. 
Serum levels of i-PTH: biochemical diagnosis of sHPT 
 
The dosage of parathyroid hormone remains an open question, due to 
the variability of several factors: 
1. Biological variability. In healthy subjects and in patients with 
primary hyperparathyroidism, PTH secretion is pulsatile, but in sHPT tonic 
and pulsatile secretion are increased and amplified as well as the frequency 
of concentration peaks. Other variable factors are age (significant increase 
with age in both sexes (+36%)), and familiarity [120]. 
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          2. Procedural variability. In order to maintain the sample stability, it 
must be considered that serum is stable up to 6 hours at 20°C before being 
frozen, and if it must be preserved for longer periods it is recommended to 
use plasma EDTA (but i-PTH serum values result 10-20% higher). 
        3. Analytical variability. Immunoassays use antibodies against the 
molecule to determine the PTH serum concentrations, so the identification 
of the antigen, and in particular the epitopes to which antibody is being 
developed, is crucial. For PTH, the problem is that there are several 
circulating molecules and they have different biological activities. 
The whole molecule of PTH is constituted by 84 amino acids, but a 
rapid hydrolysis in the parathyroid gland produces both C-terminal and N-
terminal fragments. Proteolysis can occur in different positions and it 
produces many different fragments. C-term fragments are considered to be 
biological inactive, while the N-term fragments (the most important is 1-34) 
are biologically active, and show a very short half-life. All these fragments 
are present in the serum sample for assay of PTH and, depending on the 
method used, they are detected or not. In the past it was believed that the 
biological effects of PTH resulted only from binding to specific receptors 
for PTH with affinity only for the whole molecule and the N-term fragment 
1-34. But nowadays, it is known that many C-term fragments may inhibit 
the activity of PTH, by acting on receptors expressed on osteoblasts and 
osteocytes [121]. This has had important consequences in the routine dosage 
methods of PTH, leading to the proposal of new methods. 
Assay methods. The first methods for the determination of PTH (first 
generation essays), have been completely replaced by the 
immunoradiometric assay of "second generation" that uses the technique of 
the "double antibody". The capture antibody is directed toward the C-term 
portion of the molecule (35-84), while the tracer antibody is directed toward 
the soluble N-term portion (7-34). In recent years, the IRMA methods were 
replaced by immunochemiluminometric methods (ICMA), which do not use 
radioactive markers. Third generation methods detect 1-84 PTH or "whole" 
PTH. They have been introduced because second generation assays had an 
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important weakness: the tracer antibody was directed toward the 7-34 
portion of the molecule but it was demonstrated that 30-50% of circulating 
PTH consists of N-truncated fragments of the molecule in positions 1-9, and 
in particular the fragment 7-84, biologically inactive and cross-reagent with 
the assays for intact PTH [122]. The values obtained with the whole PTH 
assay are 40-50% lower than the ones for intact PTH, both in CKD and 
healthy patients. This is ascribed to the interference due to the N-truncated 
fragments in position 1-7. At the moment, however, there is no 
recommendation to replace second-generation assays with those of third-
generation [121].          
Reference values and interpretative criteria. At present, the 
reference range proposed by K-DOQI guidelines has been set with the kit 
“Allegro” intact PTH assay (II generation IRMA method), for which the 
most widely used commercial kits showed fluctuations in the value of the 
same sample between -43% and +123%. From a practical point of view, it is 
mandatory to standardize the method by considering the sampling method 
and the kit used. Clinicians have two ways to consider the PTH values 
obtained by their laboratories: the first one is to have specific ranges for 
each kit used, while the second is to use correction factors to compare it 
with the reference values of K-DOQI guidelines. In the first case, the UK 
Renal Association recommends to maintain i-PTH levels below four times 
the upper limit of the reference method used in patients with CKD, or after 
kidney transplantation, hemodialysis or peritoneal dialysis for at least three 
months. K-DOQI guidelines (2003) recommend that i-PTH must be ranged 
between 150 and 300 pg/ml
 
.  
         
Imaging Techniques 
Ultrasonography (US) of the cervical region is the first imaging 
technique in the study of the parathyroid glands due to its repeatability, 
safety and low cost, although it needs to be performed a nephrologist which 
is expert in ultrasound. The data in the literature about sensitivity of US in 
sHPT are controversial, so they confirm the strong dependence between 
 
25 
 
results reliability and operator experience [123,124]. In a cohort of 40 
patients undergoing parathyroidectomy for severe sHPT, Jeanguillame et al. 
reported a sensitivity of 54%. Ultrasonography with ColorDoppler (US/CD) 
allows the assessment of volumetric progression over time (changes in 
diameter and volume using the ellipsoid formula 4/3 π * ½ antero-posterior 
diameter * ½ latero-lateral diameter * ½ cranio-caudal diameter) and of 
functional changes (pattern flow) of parathyroid glands, and can therefore 
highlight a mismatch between morphological and biochemical data. Adding 
these data to biochemical profile, US/CD can evidence the inadequacy of 
pharmacological treatment or a poor compliance. It also allows the timing of 
surgery. According to international guidelines, a glandular volume ≥ 500 
mm3 associated with i-PTH levels >700 pg/ml no longer controlled by 
pharmacological treatments are an indication for parathyroidectomy. The 
presence at US of a hyperplastic gland with a diameter > 1 cm is considered 
by several authors [99,125] a parameter of autonomous growth and 
irreversibility of sHPT and therefore it is an indicator of parathyroidectomy. 
Color-Doppler for the study of the parathyroid glands is performed with 
multifrequency linear probes (7.5 to 12 MHz), while in obese patients with 
goitre it can be used a low frequency probe (5 to 7.5 MHz). In clinical 
practice, we recommend an US examination when serum i-PTH >500 
pg/ml. 
Scintigraphy is essential for the presurgical localization of ectopic 
glands. The role of scintigraphy in the preoperative localization of 
hyperplastic parathyroid glands has been debated for a long time. In the past 
decades, the diagnostic accuracy of imaging techniques was often 
inadequate, so Doppman wrote the aphorism that "the only preoperative 
localization study Indicated in a patient with untreated HPT is locating an 
experienced parathyroid surgeon" [126]. Technological advances in recent 
years, however, led to a significant improvement in diagnostic accuracy of 
these methods, but with higher costs, so the discussion about their use in 
clinical practice is still open. The first tracer used since the 80s was the 
201Thallium, an analogue of potassium. There are no specific radiotracers for 
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parathyroid tissue so it is necessary to use some technical tricks to detect it: 
the double-tracer technique with subsequent subtraction of the image needs 
the administration 201Thallium and another thyroid tissue specific 
radiotracer (99mTecnetium). This technique, however, had a very poor 
accuracy (around 50%), so it has a limited use. The recent introduction of 
more selective tracers in clinical practice, as the 99m-Tc-Sestamibi and 99m 
Tc-tetraphosmine scintigraphy and SPECT-CT technology have led to an 
improvement in sensitivity and specificity. 99mTc-Sestamibi (6-methoxy-
butyl-isonitrile) is a cationic complex which shows a strong tropism for cells 
and glands with a high metabolic turnover. It is accumulated in the thyroid 
and parathyroid tissue in few minutes [127], but it is released more rapidly 
from the thyroid than from parathyroid glands: a comparison between the 
recorded image at 15 minutes and at 3 hours after administration allows 
evidencing the hyperfunctioning parathyroid tissue. SPECT provides 
information about the three-dimensional location of the lesion and about the 
topographical relationships with surrounding anatomical structures, so it is 
very useful (sensitivity greater than 90%) in difficult ectopic locations 
[128].  
Computed Tomography (CT) is used in the localization of ectopic 
mediastinal parathyroid glands. Adenomas and hyperplasia are usually 
hypodense compared to thyroid tissue; adenomas generally have a good 
contrast enhancement that makes them isodense. Nevertheless, the 
differential diagnosis between thyroid nodules, parathyroid glands and 
cervical lymph nodes can be difficult.  
Magnetic Resonance (MR) has the same indications of CT. 
Hyperplasia and adenomas are isointense with the thyroid and muscles on 
T1-weighted sequences, a hypointense on T2-weighted sequences and in 
those with fat suppression. 
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BACKGROUND OF THE STUDY 
  
 Diagnosis and treatment of sHPT are based on the dosage of serum i-
PTH, Calcium (Ca), phosphorus (P) and vitamin D. Unfortunately, the 
optimal values of PTH in maintenance hemodialysis (MHD) patients and 
peritoneal dialysis (PD) are unknown [89]. According to the K-DOQI 
guidelines, the optimal values are 150-300 pg/ml (n.v. 10-70 pg/ml) so the 
prevalence of sHPT ranges from 20-30% [18] to 47-50% [19,20]. Recent K-
DIGO guidelines indicate that in MHD i-PTH values from two to nine times 
the upper limit of normal i-PTH values
However, the dosage of i-PTH can cause diagnostic problems due to 
the heterogeneity of the molecule, the circadian and pulsatile secretion, the 
preanalytical variability (sampling times and storage conditions of blood 
sample) and the analytical variability (calibration differences between the 
different assay methods) [129]. Finally, the use of phosphate binders, 
vitamin D/analogues and calcimimetics reduces the secretion of PTH 
changing the serum levels of i-PTH regardless of the degree of hyperplasia. 
 are acceptable (140-630 pg/ml) [89]. 
So, in clinical practice biochemical data do not accurately represent 
the degree of sHPT, the glandular involvement and the structural changes 
that hyperplastic glands can show due to a response to therapy [116]. In this 
context, the role of US/CD is to integrate the biochemical diagnosis by 
defining the number, location, volume and structure of hyperplastic glands. 
Scintigraphy should be performed when US/CD is constantly negative, but 
the persistent increase of i-PTH is suspicious of an ectopic gland  [130,131]. 
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AIM OF THE STUDY 
 
The primary objective of this prospective observational study was to 
trace the epidemiology of sHPT in a population of MHD patients, based on 
biochemical parameters of mineral metabolism (serum i-PTH, Ca, P, CaXP 
product, Alkaline phosphatase)
Secondary objectives of the study were: 1) to integrate the 
biochemical and pharmacological data with the morphological data obtained 
with US/CD, 2) to study the relationship between biochemical sHPT and 
glandular volume, 3) to establish the correlation between serum i-PTH and 
total gland volume. 
 and on morphological and perfusional 
characteristics, in order to characterize the glandular hyperplasia with 
US/CD and to study the relationship between biochemical parameters and 
gland volume. 
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PATIENTS AND METHODS  
 
 Patients  
 
  We enrolled 395 patients, 269 M and 126 F, 380 in MHD and 15 in PD, 
enrolled in the Nephrology and Dialysis Units of the Hospitals of Pisa, 
Pontedera, Lucca, Barga, Castelnuovo Garfagnana, Versilia and Grosseto). 
All patients underwent US/CD examination of the neck. The examination was 
performed by two single-blinded experienced operators.  
 
 Study design  
 
  The evaluation of US/CD parameters was preceded by the collection in a 
case report format of data on age, sex, renal disease, comorbidities 
(cardiovascular, cerebrovascular, peripheral vascular diseases, cancer, 
infections), the presence of metabolic disease (diabetes mellitus, dyslipidemia) 
and risk factors such as smoke. Were recorded the parameters of mineral 
metabolism: serum calcium, phosphorus, Ca x P product, alkaline phosphatase 
and i-PTH and those of lipid metabolism (total cholesterol, HDL, LDL, 
triglycerides). In each patient we evaluated the uremic age (pre dialytic and 
dialytic age) and other parameters: Kt/V values (dialytic efficacy), systolic, 
diastolic and differential blood pressure measured before the dialysis session, 
weight after the dialysis session, calcium-phosphorus metabolism drug 
therapy. 
Methods 
 
 US/CD of the neck for the assessment of the parathyroid glands was 
performed with a portable device (My-Lab25, Esaote Biomedica, Genoa) 
and digital equipment (Logiq 9TM, General Electric Medical Systems, USA), 
with a variable frequency linear probe 9-14 MHz (axial and lateral 
resolution of 0.2 mm). Glandular flows were sampled with a transmission 
frequency of 3.8 MHz, a pulse repetition frequency (PRF) <800 kHz, a 
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steering of 20-30° and a medium-high colour gain (between 45 and 50 in a 
scale of 0-60).  
Patients were examined with the neck hyperextended in a supine decubitus. 
The anatomical location of the parathyroid glands was determined by a 
sequence of transverse, longitudinal and oblique scans in the laterocervical 
region, from the corner of the jaw to the superior mediastinum. The 
mediocervical transverse scan was essential to identify the thyroid lobes and 
isthmus. The same transverse scan along the latero-cervical line was used to 
identify the usual landmarks (sternocleidomastoid muscle, prethyroid 
muscles, epiaortic vessels, oesophagus, prevertebral muscles). Longitudinal 
and oblique scans were used to define the anatomical relationships with the 
homolateral thyroid lobe, the oesophagus, the long muscles of the neck, the 
laterocervical vessels and the thyroid and cricoid cartilages. Additional 
oblique scans were carried out on the jugular fossa to identify the inferior 
parathyroid glands, sometimes located in the superior mediastinum or in the 
horn of the thymus. The inferior thyroid artery in the mid-cervical tract was 
also located to define vascularization of parathyroid glands. 
 
B-Mode and color Doppler parameters  
 High-resolution US/CD is unable to distinguish normal parathyroid 
glands from the thyroid gland. This limit is related to the location, size, but 
also the quantity of stromal adipose tissue that makes the glands 
hyperechoic. Hyperplastic glands, however, are rich in oxyphil and main 
cells [6,9] so they become hypoechoic and more easily distinguishable. In 
our study we considered hyperplastic all glands with hypoechoic structure, 
outlined from the thyroid by a thin hyperechoic edge and with a long axis 
>5 mm. Gland volume was derived from the linear diameters using the 
irregular ellipsoid formula (4/3 π x ½ antero-posterior diameter x ½ latero-
lateral diameter x ½ cranio-caudal diameter).  
 The correlation between total glandular weight measured after surgical 
excision and PTH serum levels is good (r2 = 0.081) but not high [132]. Our 
unpublished data [133] show a linear correlation between i-PTH and 
 
31 
 
calculated gland volume in patients not treated until the total gland volume 
does not exceed 2000 mm3. In any case, these data are doubtful because the 
measurement of volume or weight after glandular excision is not a common 
practice. Studies that correlate glandular volume with histological features 
of excised glands show that glands with a volume <500 mm3 are affected 
mainly by diffuse or multinodular polyclonal hyperplasia, while glands with 
a volume >500 mm3
 At CD, hyperplastic glands showed a widespread increase in 
vascularization as confirmed by recent histological studies [134]. Three 
different vascularization patterns were identified: type 1) glands with no 
Doppler signal; type 2) hypovascularized glands with a poor or weak 
Doppler signal, represented by occasional colour spots in the 
hilar/endonodular region; type 3) hypervascularized glands, having an 
enlarged feeding artery at the hilum, a peripheral arc of vascularity and/or 
ray-like endonodular vessels. Where possible, we performed spectral 
analysis of the Doppler signal at the hilum and we determined peak systolic 
velocity (PSV) and resistance index (RI). 
 in 80% of cases are affected by monoclonal nodular 
hyperplasia [101]. 
There was no correlation between perfusion patterns and glandular 
function. A hyperfunctioning gland with a volume >500 mm3 can appear 
hypovascularized or avascularized, due to inadequate sampling (artefactual, 
deep location). In general, glands with diffuse hyperplasia and a volume 
<500 mm3 have more often a hypovascular pattern, while glands with 
nodular hyperplasia and a volume >500 mm3 were hypervascular in 78-80% 
of cases. Therefore, although vascular pattern is a semiquantitative 
parameter and it is not correlated with i-PTH, it is certainly an expression of 
increased volume and hyperfunction of the parathyroid gland
 
. 
Statistical analysis 
For the statistical analysis of data, to evaluate the difference between 
the means of two populations, we used the one-tailed z test since the 
variances of the populations compared were known and samples were large 
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enough (n1 and n2 >30). The level of significance α of the test used to reject 
the null hypothesis (H0) was p ≤ 0.05.  The statistical program used was 
Microsoft Excel ®-section Data Analysis. To assess the degree of 
homogeneity of the measurements made by two different operators we used 
the intra-class correlation coefficient (ICC). The intra-observer ICC for the 
measurement of gland volume was 0.95, while the inter-observer ICC was 
0.91. 
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RESULTS 
 
 We enrolled 395 patients (269 m, 126 f) aged 68.2 ± 14.0 (m ± SD). 
Mean dialytic age was 62.9 ± 71.3 months and mean predialytic CKD age 
was 91.4 ± 82.7 months. Clinical and biochemical parameters of the 
population are shown in Table 1, while factors causing CKD are shown in 
Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Table 1. Clinical and biochemical parameters of the population studied. 
N° of patients (m, f) 395 (269/126) 
Mean age (years) (M ± SD) 68.2±14.0 
Dialytic age (months) (M ± SD) 62.9 ± 71.3 
Predialytic CKD age (months) (M ± SD) 91.4 ± 82.7 
kt/V 1.4 ± 0.3 
BMI (kg/m2 24.9 ± 6.0 ) (M ± SD) 
Total cholesterol (mg/dl) (M ± SD) 166.2 ± 40.1 
HDL (mg/dl) (M ± SD) 42.3 ± 13.3 
LDL (mg/dl) (M ± SD) 98.8 ± 36,1 
Triglycerides (mg/dl) (M ± SD) 165.7 ± 103.3 
Ca (mg/dl) (n.v. 8.5-9.5) (M ± SD) 8.9 ± 0,8 
P (mg/dl) ( n.v. 3.5-5.5) (M ± SD) 4.7 ± 1.5 
Ca x P (mg2/dl2 41.8± 15.0 ) ( n.v. <55) (M ± SD) 
ALP (IU/l) ( n.v. 130) (M ± SD) 133.5 ± 93.1 
PTH (pg/ml) (n.v. 150-300) (M ± SD) 281.9 ± 233.4 
SBP (mmHg) (m ± SD) 136±22 
DBP (mmHg) (m ± SD) 70±12 
Differential BP (mmHg) (m ± SD) 64±21 
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Fig. 1. Causes of CKD in the population studied. 
 
108 patients (27.3%) had diabetes mellitus. Cardiovascular 
comorbidities are shown in Figure 2. 145 patients (36.7%) had one or more 
symptoms/signs of coronary artery disease [15 (10.3%) patients at least one 
episode of angina pectoris, 56 (38.6%) at least one episode of acute 
myocardial infarction (AMI), 31 (21.3%) signs and symptoms of chronic 
ischemic heart disease, and 43 (29.6%) patients had one or more cardiac 
manifestations of coronary artery disease ]. 110 patients (27.8%) had a 
history of cerebrovascular disease [11 (10%) at least one episode of TIA, 23 
(21%) at least one episode of ischemic or hemorrhagic stroke, 42 (38%) 
US/CD signs of carotid stenosis or signs of previous 
tromboendoarteriectomy (TEA), 12 (10.9%) clinical and imaging (CT, MR) 
signs of chronic ischemic encephalopathy and 22 (20%) had more 
manifestations of cerebrovascular disease]. 85 (21.5%) patients showed 
signs of ischemic lower limb arteriopathy. The blood pressure values were 
in the normal range in 95 patients (23.9%). 300 (76.1%) patients were 
hypertensive in mono/polytherapy. 
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Fig. 2. Cardiac and cerebrovascular comorbidities of the population studied. 
 
Biochemical parameters of mineral metabolism are shown in Table 1.  
Serum Ca was 8.9 ± 0.8 mg / dl, P 4.7 ± 1.5 mg / dl, Ca x P product 
41.8 ± 15.0 mg2/dl2, ALP 133.5 ± 93.1 IU/l and i-PTH 281.9 ± 233.4 pg/ml. 
According to the reference values of the K-DOQI guidelines, 252 patients 
showed values of i-PTH ≤ 300 pg/ml (144.1 ± 78.9 pg/ml) and 143 patients 
values of i-PTH> 300 pg/ml (526.6 ± 215.9 pg/ml). Based on K-DOQI 
international guidelines, 143 patients had sHPT (prevalence 36.2%). Table 
2 summarizes the parameters of mineral metabolism and the statistical 
differences between the two groups. Serum values of Ca did not differ 
significantly while P, Ca x P product and ALP were significantly different 
(P 4.6 ± 1.4 mg/dl vs 4.9 ± 1.7 mg/dl, p = 0.03, Ca x P 40.5 ± 13.6 mg2/dl2
 
 
vs 44.4 ± 16.6 p = 0.01, ALP 124.7 ± 87.2 IU/l vs 148.9 ± 101.1 IU/l, 
p=0.01) 
 
36 
 
 i-PTH ≤ 300 pg/ml i-PTH > 300 pg/ml p 
N° of patients (M/F) 252 (175/77) 143 (94/49)  
Age (years) (m ± SD) 69.2±14.1 66.7 ± 14.2 NS 
Dialytic age  
(months) (m ± SD) 
60.3 ± 76.2 67.5 ± 61.9 NS 
Predialytic CKD age  
(months) (m ± SD) 
82.7 ± 77.1 105.7 ± 89.5 0.01 
s-Ca (mg/dl) (m ± SD) 9.0 ± 0.8 9.0 ± 1.0 N.S. 
s-P (mg/dl) (m ± SD) 4.6 ± 1.4 4.9 ± 1.7 0.03 
Ca x P (mg2/dl2) (m ± SD) 40.5 ±13.8 44.4 ± 16.6 0.01 
ALP (IU/l) (m ± SD) 124.7 ± 87.2 148.4 ± 101.1 0.01 
iPTH (pg/ml) (m ± SD) 144.1 ± 78.9 526.6 ± 215.9 <0.001 
 
Table 2: Clinical and biochemical characteristics of the two groups of 
patients (i-PTH<300 pg/ml and i-PTH>300 pg/ml). 
 
Each dialysis unit used its own drug treatment schema for the control 
of mineral metabolism, so drug associations were difficult to compare. 110 
patients (28%) receive phosphate binders alone, 119 (30%) received 
phosphate binders with vitamin D analogues, 36 (9%) vitamin D analogues 
alone, 8 (2%) calcimimetic monotherapy, 12 (3%) calcimimetics and 
phosphate binders, 23 (6%) calcimimetic and vitamin D/analogues, 36 (9%) 
conventional therapy and cinacalcet. 
Finally, 51 (13%) patients did not receive any therapy for calcium-
phosphorus metabolism (Fig. 3). 
 
 
37 
 
 
Fig. 3. Drug treatment in the population studied. 
 
US/CD showed 173 parathyroid glands in 108 patients (prevalence of 
moprhological sHPT: 27.3%): 70 (64.9%) patients showed i-PTH >300 
pg/ml and 38 (35.1%) i-PTH ≤300 pg/ml. 73/287 (25.4%) patients had iPTH 
values >300 pg/ml but they didn’t show hyperplastic parathyroid glands at 
US/CD.  
214/287 (74.6%) showed values of i-PTH ≤ 300 pg/ml without 
hyperplastic parathyroid glands at US/CD.   
63 patients (58.3%) had only one hyperplastic gland, 28 (26%) two 
hyperplastic glands, 14 (13%) three hyperplastic glands, 3 (2.7%) four 
hyperplastic glands. Eleven parathyroid glands (6%) had an ectopic location 
(antero-superior mediastinum and jugular fossa). 
The structure of hyperplastic glands was almost diffusely hypoechoic 
but in some cases it showed hyperechoic septa within the hypoechoic 
parenchyma. Only in patients treated with calcimimetics and conventional 
therapy we found cystic-like lesions of different diameters associated with a 
widespread hypovascular pattern. 
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Calculated gland volume ranged from 12.5 to 3979 mm3 and the mean 
glandular volume was 257.6 ± 419.6 mm3
N° of parathyroid glands 
 (m ± SD). The US/CD 
characteristics of the glands are shown in Table 3.  
173 
Mean glandular volume (mm3 257.6 ± 419.6 ) 
N° glands with Volume ≤500 mm 153 3 
N° glands with Volume >500 mm 20 3 
Vascular pattern of glands with Volume ≤ 500 mm  3 
       Pattern 0 42/153 (27.5%) 
       Pattern 1 55/153 (36%) 
       Pattern 2 54/153 (35.5%) 
Vascular pattern of glands with Volume  > 500 mm  3 
       Pattern 0 1/20 (5 %) 
       Pattern 1 5/20 (25 %) 
       Pattern 2 14/20 (70 %) 
 
Table 3. US/CD characteristics of parathyroid glands. 
 
18 patients had at least a gland with a volume >500 mm3 and in 90 
patients each gland had volumes ≤500 mm 3. The vascular pattern of 
hyperplastic glands varied depending on gland volume: 24.9% of glands 
showed a complete absence of vascularization, 34.7% of glands showed a 
hypovascular pattern, while 40.4% of glands had a hypervascular pattern. 
Glands with a small volume showed no vascularisation or rare vascular 
signals (pattern 0 or 1), while 14 of the 20 glands with a volume >500 mm3
Based on the presence/absence of hyperplastic parathyroid glands, the 
study population could be divided into two groups: Group 1 (patients 
without morphological sHPT) and Group 2 (patients with morphological 
sHPT). The two groups differed significantly in age (p <0.001), dialytic age 
(p = 0.0002) and predialytic CKD age (p = 0.0003). Serum calcium and 
 
showed a predominantly hypervascular pattern (pattern 2) with dilation of 
the arteries, 5 glands showed a hypovascular pattern and only 1 did not 
show vascularization. These data suggest a possible correlation between 
nodular hyperplasia evidenced by US/CD and hypervascularity. In other 
words, vascular pattern could be an indirect parameter of the severity of 
glandular hyperfunction. 
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ALP showed no significant differences between the two groups, while 
serum P,  Ca x P product and i-PTH were significantly different (P 4.5 ± 1.5 
vs 5.1  ± 1.6 mg/dl, p = 0.001; Ca x P product 40.1 ± 13.5 vs 46.6  ± 17.7 
mg2/dl2, p =0.0001 and i-PTH 226.7 ± 184.4 vs 430.2  ± 282.8pg/ml, p < 
0.0001). Table 4 summarizes the differences between the two subgroups 
and Fig. 4 and Fig. 5 show the differences in etiology of CKD between the 
two groups. Finally, patients with parathyroid hyperplasia and i-PTH ≤300 
pg/ml showed a mean glandular volume of 169.8 ± 251.4 mm3, whereas 
patients with parathyroid hyperplasia and i-PTH >300 pg/ml had a mean 
glandular volume of 295.4 ± 468.7 mm3
 
 (p = 0.07). 
 
Table 4. Clinical and biochemical characteristics of patients with and 
without morphological sHPT. 
    
Absence of 
morphological 
sHPT  
Morphological 
sHPT  
p 
N° of patients (m/f)  287 (201/86) 108 (68/40)  
Mean age (years) (m±SD) 70.4 ± 13.4 62.6± 14.2 <0.001 
Mean dialytic age 
(months) (m±SD) 
54.9 ± 69.5 84.4  ± 72.0 0.0002 
Mean predialytic CKD age 
(months) (m±SD) 
82.3 ± 75.6 115.3  ± 95.0 0.0003 
s-Ca (mg/dl) (m ± SD) 8.9 ± 0.8 9.1  ± 0.9 N.S. 
s-P (mg/dl) (m ± SD) 4.5 ± 1.5 5.1  ± 1.6 0.001 
Ca x P (mg2/dl2) (m ± SD) 40.1 ± 13.5 46.6  ± 17.7 0.0001 
ALP (IU/l) (m ± SD) 129.6 ± 90.2 143.4  ± 99.8 N.S. 
iPTH (pg/ml) (m ± DS) 226.7 ± 184.4 430.2  ± 282.8 < 0.0001 
PAS (mmHg) (m ± DS) 135.8 ± 20.7 135.0  ± 23.9 N.S. 
PAD (mmHg) (m ± DS) 69.2 ± 11.3 70.8  ± 14.1 N.S. 
 
40 
 
 
Fig. 4. Causes of CKD in patients without morphological sHPT. 
 
 
 
 
 
 
Fig 5. Causes of CKD in patients with morphological sHPT. 
 
The correlation between i-PTH serum levels and total glandular (Fig. 
6) showed a linear trend regardless of the current treatment. The equation of 
the linear regression line was glandular volume = 0.8995 * (i-PTH) + 15.3. 
The Pearson correlation coefficient was R = 0.3694, and R2 = 0.1365 (p = 
0.001). 
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Fig. 6. Linear correlation between i-PTH and glandular volume. 
 
 Figure 7 shows the normal distribution in the groups with and without 
US/CD evidence of sHPT based on serum levels of i-PTH: the intersection 
of the two curves (i-PTH = 389 pg/ml) represents the point in which patients 
have the same probability to have both biochemical and morphological 
sPTS or a clinical situation in which there is a hypersecretion (i-PTH >300 
pg/ml) without US/CD evidence of hyperplasia. 
 
 
Fig. 7. Normal distribution of i-PTH serum levels in patients with and 
without US/CD evidence of glandular hyperplasia. 
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 DISCUSSION 
 
In the population studied, epidemiological data show that the mean 
age of prevalent patients (68.2±14.0 years) is similar to that reported in the 
DOPPS3-2007 study (66.1 ± 13.5 years) and significantly higher than the 
one reported in the Italian DOPPS cohort study referred to the year 2002 
(61.4 years) [135]. The aging of the dialysis population is accompanied by 
changes in CKD causes. In our cohort chronic atherosclerotic vascular 
disease (19%), diabetes (18%) and CKD of unknown cause (16%) are 
prevalent. 
 The highest values of i-PTH associated with nodular hyperplasia were 
detected in patients with a very long dialytic age (84.4 ± 72.0 months) and 
predialytic CKD age (115.3 ± 95.0 months), i.e. in patients with primitive 
nephropaties or congenital-hereditary diseases. Therefore, we can suppose 
that in the future the clinical history of sHPT will assume different 
epidemiological aspects, because nowadays most of incident patients in 
hemodialysis are old patients with several cardiovascular comorbidities 
associated with short predialytic age. 
In our series, severe sHPT and parathyroid nodular hyperplasia occurs 
in patients with a very long dialytic (84.4 ± 72.0 months) and predialytic 
(115.3 ± 95.0 months) age, depending on the prevalence of the different 
causes of CKD. In fact, primitive chronic glomerulonephritis (18%), 
hereditary diseases (18%) and congenital-family (8%) were prevalent in our 
108 patients with evidence of glandular hyperplasia. However, the 
prevalence of chronic atherosclerotic vascular nephropathy, diabetes 
mellitus and unknown causes was not negligible. 
The current availability of drugs that correct the deficit of vitamin D, 
calcium imbalance and hyperphosphatemia, implies a very careful clinical 
evaluation of every patient with sHPT, in order to choose the most 
appropriate drug schema. According to international guidelines, diagnosis 
and pharmacological treatments are based on periodic evaluation of serum  
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i-PTH levels and of the parameters of mineral metabolism, although i-PTH 
dosage is a measure of the functional status and it does not provide any 
information on the morphological status of the parathyroid glands. K-DOQI 
guidelines consider acceptable i-PTH values between 150 and 300 pg/ml in 
hemodialysis patients [89], while the recent K-DIGO guidelines [90] 
consider acceptable i-PTH values from 2 to 9 times the upper limit of 
normal range (140-630 pg/ml). If we analyze our cohort according to the K-
DOQI criteria we evidence that patients with i-PTH> 300 pg/ml were 36.2% 
(143/395), while patients with i-PTH <300 pg/ml were the 63.8% (252/395). 
Based on the K-DIGO criteria, only 9% of the population (36 patients) had 
values of i-PTH >630 pg/ml, i.e. values that are compatible with a severe 
sHPT. 
The inability to establish the grading of sHPT in patients that show  i-
PTH serum levels in the range of the international guidelines is a limiting 
factor for the therapeutic approach and it demonstrates that the current 
knowledge about the mechanisms that regulate the homeostasis of mineral 
metabolism is still incomplete and should be clarified by experimental and 
clinical studies, in order to establish the optimum levels of serum i-PTH in 
hemodialysis patients. 
 Currently we do not have morphological and functional imaging 
techniques able to study the normal parathyroid glands and to characterize 
the progression to glandular hyperplasia. In several studies, the sensitivity 
and specificity of scintigraphy with sestamibi scintigraphy and SPECT-CT 
range from 50 to 60% [125-127], while CT and MR are not routinely used 
for the diagnosis and monitoring of sHPT. 
 So, US/CD is the only repeatable and noninvasive technique which is 
sensitive enough to assess the presence of hyperplasia and the progression 
of sHPT. The main limitations of US/CD are related to the sensitivity and 
specificity of the method (small size gland, ectopic or deep location), to the 
operator experience and to the technical difficulties and differential 
diagnosis (multinodular goiter, thyroidectomy, reactive lymph nodes, 
thymic horn). In a study of 40 consecutive patients undergoing total 
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parathyroidectomy, the  sensitivity, specificity, positive predictive value and 
accuracy of US/CD in the diagnosis of hyperplasia was 74%, 75%, 98% and 
74% respectively [136]. In the same study, the sensitivity reaches 90% if the 
gland volume was ≥ 500 mm3
 
 (glandular diameter >1 cm). 
If we consider the two tests (i-PTH and US/CD) at the same time, 
each patient of the cohort studied was included in one of the four groups 
described in Table 5. 
 
US/CD 
evidence of 
sHPT   
No 
(287 pts) 
i-PTH ≤300 
pg/ml 
214/287 pts 
(74.6%) 
1- Prevalent patients with short 
dialytic/predialytic CKD age 
2- Adequate drug therapy and good patient 
compliance 
3- Parathyroidectomy (Ptx) 
4-  Low turnover bone disease 
i-PTH >300 
pg/ml 
73/287 pts 
(25.4%) 
1- Inadequacy of drug treatment 
2- Poor therapeutic compliance  
3- Sensitivity limits of US/CD (false 
negatives) 
US/CD 
Evidence of 
sHPT  
(108 pts) 
i-PTH ≤300 
pg/ml 
38/108 pts 
(35.2%) 
1- Adequate drug therapy and good patient 
compliance 
2- False positives 
i-PTH >300 
pg/ml 
70/108 pts 
(64.8%) 
1- Need of a more aggressive therapy.  
2- Glands with higher volumes (Ptx?) 
 
Table 5. Subdivision of patients studied based on the 
concordance/discordance between i-PTH serum levels and US/CD. Pts= 
patients. 
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For each group we report the drug therapy concerning the calcium-
phosphorus metabolism. (Figures 8, 9). 
 
 
 
 
Fig. 8. Pharmacological treatment of patients with i-PTH<300 pg/ml and no 
evidence of hyperplastic parathyroid glands at US/CD (a); pharmacological 
tratment of patients with i-PTH>300 pg/ml and no evidence of hyperplastic 
parathyroid glands at US/CD (b). 
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 Fig. 9. Pharmacological therapy in patients with i-PTH >300 pg/ml and 
glandular hyperplasia at US/CD (a); Pharmacological therapy in patients 
with i-PTH <300 pg/ml and glandular hyperplasia at US/CD (b). 
 
In our cohort, the match between US/CD findings and i-PTH values 
showed that 287/395 patients (72.6%) had no glandular hyperplasia. In 214 
of these patients (74.6%) i-PTH was ≤ 300 pg/ml, while in 73 (25.4%) i-
PTH was >300 pg/ml. In the first case, the biochemical and morphological 
test agreed, while in the second case they were discordant. The match may 
be justified by the inclusion in the first subgroup of patients without signs of 
hyperfunctioning glands (prevalent patients with short dialytic and 
predialytic CKD age), patients with adequate and good compliance to 
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treatment (including patients undergoing subtotal parathyroidectomy) (Fig. 
8a), patients who underwent total parathyroidectomy and finally, patients 
with signs of iatrogenic ABD. 
There are many explanation for the discrepancy between i-PTH serum 
levels and the absence of glandular hyperplasia in the second case. The high 
values of i-PTH may be an expression of a phase of hormonal 
hyperincretion sustained by a hypertrophy/hyperplasia that is still not 
evident at US/CD. Another hypothesis is that these values of i-PTH may be 
related to an inappropriate treatment or to a lack of nutritional or therapeutic 
compliance (Fig. 8b). 
Finally, the discrepancy could be due to a true false negative at 
US/CD or a false negative due to the presence of initial hyperplasia. The 
discrepancy in this subgroup identifies a window period in which the 
hyperincretion is associated with hypertrophy/hyperplasia that can be easily 
dominated with a more aggressive therapy. These patients should undergo 
careful monitoring because if they are not well treated they could 
progressively develop nodular hyperplasia. 
 Matching US/CD findings with the i-PTH serum levels we evidence that 
108/395 patients (27.3%) showed hyperplasia of the parathyroid glands 
associated in 64.8% of cases (70/108) to an i-PTH >300 pg/ml and in 35.2% 
(38/108) to an i-PTH <300 pg/ml. In the first case the two tests identify a 
dialysis population in which glandular hyperfunction coincided with the 
morphological data. In these patients drug therapy should be more 
aggressive. In fact, if the volume of each glands is <500 mm3 (diffuse 
hyperplasia) the possibility that drug treatment could control sHPT is very 
high. If, however, one or more glands show a volume >500 mm3 (nodular 
hyperplasia with down-regulation of VDR and CaR) there is a severe sHPT 
for which treatment options are limited to conventional therapy associated 
with cinacalcet or to parathyroidectomy (Fig. 9a). In the second subgroup, 
glandular hyperplasia did not coincide with serum i-PTH levels. This 
discrepancy between the two tests may be justified by: a) the efficacy of 
drug treatment that act on small volume glands which are still sensitive to 
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the stimulus receptor (Fig. 9b), b) the good patient therapeutic compliance, 
c) an US/CD false positive.  
  If we consider the range of variation of i-PTH levels in the group that 
showed morphologic evidence of hyperplasia and in the group that did not 
(430.2 ± 282.8 vs 226.7 ± 184.4) we can observe an important overlapping 
(Fig. 7). Therefore, US/CD of parathyroid glands should be performed when 
i-PTH serum levels are constantly >400 pg/ml. Scintigraphy should be 
performed in those cases in which the persistent increase in PTH is 
associated with several negative US/CD examinations. Once morphological 
sHPT has been characterized, US/CD of the neck should be repeated 
annually to evaluate the progression of the disease [136]. 
Finally, if we match the results of US/CD with i-PTH serum levels 
recommended by the K-DIGO guidelines, it appears that 273/287 patients 
(95.1%)  without glandular hyperplasia showed a i-PTH ≤630 pg/ml and 
14/287 patients (4.9%) a i-PTH >630 pg/ml (Table 6). In patients with 
glandular hyperplasia, there was a correlation between i-PTH values and 
glandular hyperplasia in 22 cases (20.4%), while in 79.6% of cases (86/108 
patients) i-PTH values did not agree with the morphological data. The 
critical analysis of data in Table 6 highlights that the new guidelines tend to 
extend too much the acceptable range of i-PTH values in hemodialysis 
patients. This wide range allows a correct selection of patients with severe 
sHPT but, however, it tends to consider acceptable clinical situations where 
the coexistence of biochemical and morphological sHPT recommend a more 
aggressive and focused pharmacological treatment. 
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US/CD evidence of sHPT   
No 
(287 pts) 
≤630 pg/ml 
95.1% (273/287 pts)  
>630 pg/ml 
4.9% (14/287 pts)  
US/CD evidence of sHPT   
 (108 pts) 
≤630 pg/ml 
79.6% (86/108 pts) 
>630 pg/ml 
20.4% (22/108 pts)  
 
Table 6. Concordance/discordance between i-PTH and glandular 
hyperplasia based on serum i-PTH levels of K-DIGO International 
guidelines (pts = patients). 
 
In summary, the analysis of these data leads to three considerations: 1) 
at the moment, i-PTH values and ultrasound examination alone do not 
provide an accurate assessment of the parathyroid hyperfunctioning state; 2) 
the association between biochemical and morphological evaluation is the 
best way to diagnose sHPT, in the absence at present of a gold standard 
diagnostic test. The definition of the number, location and volume of 
hyperplastic glands associated with the determination of i-PTH serum levels 
also provides a clear indication of the efficacy of current treatment and the 
patient compliance, 3) the i-PTH dosage is a measure of the functional 
status of parathyroid glands but it does not provide any information on the 
morphological status of glands. So, if i-PTH serum levels are constantly 
>400 pg/ml it is necessary to perform an US/CD of the neck to evaluate the 
presence of hyperplastic glands and to begin a combined follow-up, in order 
to guide any changes in drug therapy and to indicate the timing of surgery. 
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CONCLUSIONS 
 
         The prevalence biochemical sHPT is 36.2% while the prevalence of 
morphological sHPT is 27.3%. These prevalence rates are likely to change 
over time, due to important changes in the clinical characteristics of incident 
hemodialysis patients (age, underlying renal disease, dialytic and predialytic 
CKD age), so further epidemiologic investigations are needed. 
 i-PTH serum levels are expression of the functional status of glands, but 
it is a parameter characterized by wide intrapersonal, intra-analytical and 
inter-analytical variability, and it does not provide any information on the 
morphological status of the parathyroid glands. 
At present, we do not have morphological and functional imaging 
techniques able to study the normal parathyroid glands and to characterize 
the progression of glandular hyperplasia. In several studies, the sensitivity 
and specificity of scintigraphy with sestamibi scintigraphy and SPECT-CT 
ranged from 50 to 60%, while CT and MR are not routinely used for 
diagnosis and monitoring of sHPT. So, US/CD is the only repeatable and 
noninvasive technique which is ensitive enough to assess the presence of 
hyperplasia and the progression of sHPT. The main limitations of US/CD 
are related to the sensitivity and specificity of the method (small size gland, 
ectopic or deep location), to the operator experience and to the technical 
difficulties and differential diagnosis (multinodular goiter, thyroidectomy, 
reactive lymph nodes, thymic horn). We can deduce that US/CD alone is not 
able to lead to a precise diagnosis of sHPT. 
This epidemiological study shows that using both biochemical and 
morphological data it is possible to better characterize sHPT and to correctly 
guide pharmacological treatment. So if i-PTH serum levels are >400 pg/ml 
it is necessary to perform an US/CD examination of the neck to document 
the presence of hyperplastic glands. The biochemical evaluation associated 
with the morphological characterization is the most complete way to make 
the diagnosis of sHPT. The definition of the number, location and volume of 
the hyperplastic glands associated with the determination of i-PTH serum 
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levels also provides a clear indication of the efficacy of the current treatment 
and the patient compliance. 
The major limitation of this study is the lack of a gold standard test for 
sHPT, in order to allow a critical analysis of the validity of the two tests in 
the diagnosis of sHPT. In clinical practice, the limitations related to  PTH 
dosage are overcome by analyzing the trend in the last three determinations. 
The limits of sensitivity and specificity of ultrasound can be solved by 
repeating the test every six months to observe the appearance of any 
hyperplastic glands or to evaluate the volume progression.  
Ectopic glands represent a limited problem because in sHPT 
hyperplasia does not affect only one gland but all of them, although nou 
uniformly.  
Finally, in this study we have not estimated the values of FGF-23 and 
25-OH-vitamin D. This would have completed the biochemical and 
epidemiological characterization of dialysis patients; recent studies, in fact, 
show a linear correlation (r = 0.3, p <0.001) between biochemical sHPT and 
25-OH-vitamin D [137]. 
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